Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05255484 · ClinicalTrials.gov registry record · Phase 1
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
A Phase 1 study, sponsored by LaNova Medicines Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05255484 is a Phase 1 study that was terminated before completion, run by LaNova Medicines Limited. The registered enrollment target is 24 participants.
The verdict
NCT05255484, a Phase 1 study, was terminated before completion, sponsored by LaNova Medicines Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors
Interventions
- DRUG LM-108
- DRUG An Anti-PD-1 Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05255484
The ClinicalTrials.gov registry entry for NCT05255484 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LaNova Medicines Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LM-108 is the first listed.
NCT05255484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05255484 about?
NCT05255484 is a clinical study titled "Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours". A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors
What is the current status of trial NCT05255484?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-05-26. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT05255484?
The interventions under investigation include: LM-108 (DRUG), An Anti-PD-1 Antibody (DRUG).
Who is sponsoring clinical trial NCT05255484?
This trial is sponsored by LaNova Medicines Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.